as of march 2022. sf1126 is a peptidic prodrug targeting integrin receptors that converts to ly294002, one of the most widely studied dual pi3k/mtor inhibitors. a phase ii trial with sf1126 has been terminated due to slow enrolment. early stage in early stage clinical trials acalisib (codenamed cal-120, gs-9820) has completed one phase i trial in 2016. no data have been published for this trial and no further trials have been conducted since then as of march 2022. omipalisib (codenamed gsk2126458, gsk458) has completed two phase i trials in 2015 and 2016, respectively. no data have been published for these trials and no further trials have been conducted since then as of march 2022. azd8835 (pik3ca and pik3cd inhibitor) has completed one phase i trial in 2016. no data have been published for this trial and no further trials have been conducted since then as of march 2022. cal263 (pik3cd inhibitor) gsk1059615 (dual pan-class i pi3k and mtor inhibitor): the phase i trial of this drug was terminated due to lack of sufficient exposure following single- and repeat-dosing. men1611 (ch5132799, pa799; mainly a pik3ca inhibitor) will be tested in a phase i/ii trial with pik3ca-mutated colorectal cancer patients that is currently recruiting patients as of march 2022. pwt33597 (dual pik3ca and mtor inhibitor) tg100-115 (mainly a pik3cd and pik3cg inhibitor) zstk474 (mainly a pik3cd inhibitor) not in clinical trials aezs-136 (dual pi3k and erk inhibitor) b591 (pan-class i pi3k inhibitor) gne-477 (dual pik3ca and mtor inhibitor with ic50 values of 4 nm and 21 nm) hibiscone c (irreversible pi3k inhibitor) ic87114 (mainly a pik3cd inhibitor) ly294002 (reversible pi3k inhibitor), mainly used as a research tool pi-103 (triple pan-class i pi3k, mtor, and dna-pk inhibitor) wortmannin (irreversible pi3k inhibitor), mainly used as a research tool